US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

36.49

+0.54001.50%

Volume:8.70K

Turnover:314.74K

Market Cap:2.83B

PE:-18.21

High:36.85

Open:36.05

Low:36.05

Close:35.95

52wk High:37.98

52wk Low:10.91

Shares:77.59M

Float Shares:63.83M

Volume Ratio:1.17

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0036

EPS(LYR):-3.1802

ROE:-38.08%

ROA:-30.20%

PB:9.46

PE(LYR):-11.47

Loading ...

Overview Company News Filings

Spyre Therapeutics presents 20-week Phase 1 SPY003 data at ECCO 2026

Spyre Therapeutics vergibt neue Aktienoptionen an Mitarbeiter als Vergütungsanreiz

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics CEO Cameron Turtle Reports Sale of Common Shares

Spyre Therapeutics Grants Stock Options to New Chief Commercial Officer

Spyre Therapeutics Appoints Kate Chevlen as Chief Commercial Officer

Spyre Therapeutics Announces Grants of Inducement Awards

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Spyre Therapeutics (SYRE) and Astellas Pharma (OtherALPMF)

Wedbush Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO

BRIEF-Spyre Therapeutics Inc - Skyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule

Spyre Therapeutics Appoints Kate Tansey Chevlen as Chief Commercial Officer

Spyre Therapeutics Inc - Skyline Trial in Uc Completes Spy001 Enrollment Ahead of Schedule

THOMSON REUTERS

Spyre Therapeutics Inc: Skyline Part a Readouts Accelerated, NOW Expected to Start in Q2

THOMSON REUTERS

Spyre Therapeutics Inc - Skyway Trial Readouts Expected in 4Q 2026

THOMSON REUTERS

Press Release: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Spyre Therapeutics Grants Stock Options to Six New Employees

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics CEO Cameron Turtle Reports Disposal of Common Shares

Spyre Therapeutics (SYRE) Valuation Check After Recent Drop And Focus On 2026 Trial Readouts

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SYRE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":36.49,"timestamp":1771425174094,"preClose":35.95,"halted":0,"volume":8698,"delay":0,"changeRate":0.015020862308762145,"floatShares":63829799,"shares":77592130,"eps":-2.003614,"marketStatus":"Trading","change":0.54,"latestTime":"02-18 09:33:20 EST","open":36.05,"high":36.85,"low":36.05,"amount":314743.114224,"amplitude":0.022253,"askPrice":36.98,"askSize":327,"bidPrice":36.09,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-2.003614,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771448400000},"marketStatusCode":2,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":35.95,"preHourTrading":{"tag":"盘前","latestPrice":37.04,"preClose":35.95,"latestTime":"09:29 EST","volume":35,"amount":1279.4200999999998,"timestamp":1771424952381,"change":1.09,"changeRate":0.03032,"amplitude":0.077051},"postHourTrading":{"tag":"盘后","latestPrice":35.95,"preClose":35.95,"latestTime":"19:06 EST","volume":28611,"amount":1028564.7412,"timestamp":1771373162411,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.166502,"impliedVol":0.8005,"impliedVolPercentile":0.6534},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":63829799,"roa":"-30.20%","roe":"-38.08%","lyrEps":-3.180151,"volumeRatio":1.166502,"shares":77592130,"dividePrice":0,"high":36.85,"amplitude":0.022253,"preClose":35.95,"low":36.05,"week52Low":10.91,"pbRate":"9.46","week52High":37.98,"institutionHeld":0,"latestPrice":36.49,"committee":-0.884726,"eps":-2.003614,"divideRate":0,"volume":8698,"delay":0,"ttmEps":-2.003614,"open":36.05,"prevYearClose":32.76,"prevWeekClose":36.63,"prevMonthClose":31.98,"prevQuarterClose":32.76,"fiveDayClose":33.56,"twentyDayClose":33.73,"sixtyDayClose":24.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-04","symbol":"SYRE","fiscalQuarterEnding":"2025/09","expectedEps":-0.68,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-08-05","symbol":"SYRE","fiscalQuarterEnding":"2025/06","expectedEps":-0.73,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-05-08","symbol":"SYRE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2025-02-27","symbol":"SYRE","fiscalQuarterEnding":"2024/12","expectedEps":-1.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"SYRE","fiscalQuarterEnding":"2024/09","expectedEps":-0.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.36}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":15,"updateTime":1766293200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2026-02-17","current":-17.942578,"percent":0,"low":-19.079135,"twenty":-7.914537,"median":-4.904915,"eighty":-3.895953,"high":-0.199399,"avg":-6.493813,"sd":4.070686,"marketCap":2842199721},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-4.872934,"twenty":-4.111605,"median":-3.38639,"eighty":-2.608303,"marketCap":1774844320},{"date":"2024-06-07","current":-4.694469,"twenty":-4.171641,"median":-3.527045,"eighty":-2.61809,"marketCap":1709842869},{"date":"2024-06-14","current":-4.393309,"twenty":-4.193693,"median":-3.59738,"eighty":-2.63375,"marketCap":1600152919},{"date":"2024-06-21","current":-3.360163,"twenty":-4.181695,"median":-3.573485,"eighty":-2.653814,"marketCap":1223855454},{"date":"2024-06-28","current":-3.277902,"twenty":-4.180281,"median":-3.545724,"eighty":-2.666048,"marketCap":1193893847},{"date":"2024-07-05","current":-3.553965,"twenty":-4.180278,"median":-3.545724,"eighty":-2.674367,"marketCap":1294442968},{"date":"2024-07-12","current":-4.13816,"twenty":-4.17596,"median":-3.564426,"eighty":-2.694186,"marketCap":1507221157},{"date":"2024-07-19","current":-4.113063,"twenty":-4.180278,"median":-3.593701,"eighty":-2.712782,"marketCap":1498080328},{"date":"2024-07-26","current":-4.387732,"twenty":-4.219183,"median":-3.614061,"eighty":-2.731867,"marketCap":1598121624},{"date":"2024-08-02","current":-3.651563,"twenty":-4.192391,"median":-3.674487,"eighty":-2.752053,"marketCap":1329990636},{"date":"2024-08-09","current":-6.773008,"twenty":-4.238871,"median":-3.689208,"eighty":-2.757559,"marketCap":1259650875},{"date":"2024-08-16","current":-7.111659,"twenty":-4.267009,"median":-3.707046,"eighty":-2.757559,"marketCap":1322633418},{"date":"2024-08-23","current":-6.972375,"twenty":-4.305721,"median":-3.744862,"eighty":-2.758537,"marketCap":1296729308},{"date":"2024-08-30","current":-7.851774,"twenty":-4.372067,"median":-3.796365,"eighty":-2.792303,"marketCap":1460280752},{"date":"2024-09-06","current":-7.655166,"twenty":-4.395693,"median":-3.839237,"eighty":-2.844176,"marketCap":1423715511},{"date":"2024-09-13","current":-8.038472,"twenty":-4.515004,"median":-3.909092,"eighty":-2.863261,"marketCap":1495003126},{"date":"2024-09-20","current":-8.260242,"twenty":-4.753435,"median":-3.923931,"eighty":-2.887484,"marketCap":1536248103},{"date":"2024-09-27","current":-7.800275,"twenty":-4.893011,"median":-3.931452,"eighty":-2.904612,"marketCap":1450702965},{"date":"2024-10-04","current":-7.980976,"twenty":-5.268067,"median":-3.990592,"eighty":-2.931282,"marketCap":1484309983},{"date":"2024-10-11","current":-7.857771,"twenty":-6.760445,"median":-4.004311,"eighty":-2.936176,"marketCap":1461396107},{"date":"2024-10-18","current":-8.969358,"twenty":-6.959266,"median":-4.01434,"eighty":-2.939112,"marketCap":1668130191},{"date":"2024-10-25","current":-9.530627,"twenty":-7.262959,"median":-4.019298,"eighty":-2.969942,"marketCap":1772515627},{"date":"2024-11-01","current":-9.303382,"twenty":-7.505129,"median":-4.04736,"eighty":-3.046528,"marketCap":1730252255},{"date":"2024-11-08","current":-9.47125,"twenty":-7.585076,"median":-4.070861,"eighty":-3.057293,"marketCap":2035390531},{"date":"2024-11-15","current":-6.988263,"twenty":-7.603794,"median":-4.087936,"eighty":-3.101825,"marketCap":1501791624},{"date":"2024-11-22","current":-7.566995,"twenty":-7.593388,"median":-4.106049,"eighty":-3.128495,"marketCap":1626162294},{"date":"2024-11-29","current":-7.766414,"twenty":-7.602508,"median":-4.133831,"eighty":-3.149049,"marketCap":1669017834},{"date":"2024-12-06","current":-7.397625,"twenty":-7.602508,"median":-4.146835,"eighty":-3.16373,"marketCap":1589764437},{"date":"2024-12-13","current":-6.589022,"twenty":-7.597044,"median":-4.169482,"eighty":-3.166361,"marketCap":1415994026},{"date":"2024-12-20","current":-6.517996,"twenty":-7.595055,"median":-4.180278,"eighty":-3.169847,"marketCap":1400730409},{"date":"2024-12-27","current":-6.466093,"twenty":-7.588386,"median":-4.182047,"eighty":-3.186241,"marketCap":1389576227},{"date":"2025-01-03","current":-6.651853,"twenty":-7.58308,"median":-4.215671,"eighty":-3.191991,"marketCap":1429496457},{"date":"2025-01-10","current":-6.135549,"twenty":-7.579794,"median":-4.247699,"eighty":-3.203592,"marketCap":1318541701},{"date":"2025-01-17","current":-5.632904,"twenty":-7.573901,"median":-4.253955,"eighty":-3.236074,"marketCap":1210522256},{"date":"2025-01-24","current":-5.900617,"twenty":-7.564263,"median":-4.27898,"eighty":-3.264517,"marketCap":1268054352},{"date":"2025-01-31","current":-6.280332,"twenty":-7.548513,"median":-4.304099,"eighty":-3.280514,"marketCap":1349655997},{"date":"2025-02-07","current":-6.187452,"twenty":-7.528128,"median":-4.345056,"eighty":-3.293411,"marketCap":1329695883},{"date":"2025-02-14","current":-6.26121,"twenty":-7.522652,"median":-4.382852,"eighty":-3.305947,"marketCap":1345546562},{"date":"2025-02-21","current":-5.815932,"twenty":-7.518271,"median":-4.394799,"eighty":-3.316941,"marketCap":1249855423},{"date":"2025-02-28","current":-5.708297,"twenty":-7.512359,"median":-4.473117,"eighty":-3.319102,"marketCap":1187428551},{"date":"2025-03-07","current":-5.647447,"twenty":-7.483663,"median":-4.605135,"eighty":-3.349687,"marketCap":1174770683},{"date":"2025-03-14","current":-5.227293,"twenty":-7.452562,"median":-4.749486,"eighty":-3.357028,"marketCap":1087371120},{"date":"2025-03-21","current":-5.264962,"twenty":-7.449529,"median":-4.833391,"eighty":-3.360163,"marketCap":1095206943},{"date":"2025-03-28","current":-5.198317,"twenty":-7.397625,"median":-4.89803,"eighty":-3.364368,"marketCap":1081343564},{"date":"2025-04-04","current":-3.706047,"twenty":-7.375771,"median":-4.833391,"eighty":-3.376602,"marketCap":770924425},{"date":"2025-04-11","current":-3.540883,"twenty":-7.371109,"median":-4.749486,"eighty":-3.378289,"marketCap":736567355},{"date":"2025-04-17","current":-3.671275,"twenty":-7.352984,"median":-4.694469,"eighty":-3.38477,"marketCap":763691357},{"date":"2025-04-25","current":-4.094327,"twenty":-7.328784,"median":-4.51381,"eighty":-3.412624,"marketCap":851693676},{"date":"2025-05-02","current":-4.378293,"twenty":-7.296115,"median":-4.473117,"eighty":-3.422161,"marketCap":910763726},{"date":"2025-05-09","current":-4.072986,"twenty":-7.269514,"median":-4.422481,"eighty":-3.450063,"marketCap":850985210},{"date":"2025-05-16","current":-4.384959,"twenty":-7.258044,"median":-4.393309,"eighty":-3.492778,"marketCap":916167055},{"date":"2025-05-23","current":-4.353184,"twenty":-7.252035,"median":-4.386346,"eighty":-3.506946,"marketCap":909528164},{"date":"2025-05-30","current":-4.491839,"twenty":-7.242247,"median":-4.381626,"eighty":-3.527827,"marketCap":938497873},{"date":"2025-06-06","current":-4.800924,"twenty":-7.228256,"median":-4.393309,"eighty":-3.543713,"marketCap":1003076183},{"date":"2025-06-13","current":-5.115786,"twenty":-7.156112,"median":-4.413455,"eighty":-3.545748,"marketCap":1068861565},{"date":"2025-06-20","current":-4.356073,"twenty":-7.062301,"median":-4.413455,"eighty":-3.549094,"marketCap":910131699},{"date":"2025-06-27","current":-4.627605,"twenty":-6.984824,"median":-4.413846,"eighty":-3.558149,"marketCap":966864047},{"date":"2025-07-03","current":-4.5525,"twenty":-6.978207,"median":-4.413846,"eighty":-3.566238,"marketCap":951172121},{"date":"2025-07-11","current":-4.610273,"twenty":-6.959266,"median":-4.434912,"eighty":-3.576816,"marketCap":963242833},{"date":"2025-07-18","current":-4.878917,"twenty":-6.905553,"median":-4.448509,"eighty":-3.590436,"marketCap":1019371645},{"date":"2025-07-25","current":-5.084011,"twenty":-6.899536,"median":-4.462257,"eighty":-3.592447,"marketCap":1062222673},{"date":"2025-08-01","current":-4.902026,"twenty":-6.889009,"median":-4.488402,"eighty":-3.59611,"marketCap":1024199930},{"date":"2025-08-08","current":-4.450911,"twenty":-6.843738,"median":-4.500505,"eighty":-3.597671,"marketCap":920510630},{"date":"2025-08-15","current":-4.924039,"twenty":-6.770823,"median":-4.509171,"eighty":-3.60188,"marketCap":1018360185},{"date":"2025-08-22","current":-4.900675,"twenty":-6.760445,"median":-4.52404,"eighty":-3.616232,"marketCap":1013528108},{"date":"2025-08-29","current":-4.883151,"twenty":-6.744059,"median":-4.5525,"eighty":-3.624946,"marketCap":1009904051},{"date":"2025-09-05","current":-4.962006,"twenty":-6.704732,"median":-4.610273,"eighty":-3.625072,"marketCap":1026212310},{"date":"2025-09-12","current":-4.731283,"twenty":-6.670975,"median":-4.650968,"eighty":-3.630649,"marketCap":978495552},{"date":"2025-09-19","current":-4.474275,"twenty":-6.670975,"median":-4.610273,"eighty":-3.651563,"marketCap":925342707},{"date":"2025-09-26","current":-4.558971,"twenty":-6.651853,"median":-4.590463,"eighty":-3.659766,"marketCap":942858985},{"date":"2025-10-03","current":-4.667031,"twenty":-6.651853,"median":-4.640746,"eighty":-3.671275,"marketCap":965207340},{"date":"2025-10-10","current":-6.182794,"twenty":-6.639187,"median":-4.66411,"eighty":-3.682866,"marketCap":1278688323},{"date":"2025-10-17","current":-6.495292,"twenty":-6.589022,"median":-4.675298,"eighty":-3.682866,"marketCap":1343317350},{"date":"2025-10-24","current":-8.382293,"twenty":-6.651853,"median":-4.679157,"eighty":-3.689208,"marketCap":1733575542},{"date":"2025-10-31","current":-9.090497,"twenty":-6.704732,"median":-4.696933,"eighty":-3.700564,"marketCap":1880042140},{"date":"2025-11-07","current":-11.662076,"twenty":-6.790267,"median":-4.714264,"eighty":-3.706047,"marketCap":1737287790},{"date":"2025-11-14","current":-11.787083,"twenty":-6.900444,"median":-4.731283,"eighty":-3.707046,"marketCap":1755909901},{"date":"2025-11-21","current":-12.224606,"twenty":-6.988263,"median":-4.745208,"eighty":-3.707046,"marketCap":1821087291},{"date":"2025-11-28","current":-15.625828,"twenty":-7.239349,"median":-4.751954,"eighty":-3.713244,"marketCap":2327763900},{"date":"2025-12-05","current":-17.454049,"twenty":-7.296115,"median":-4.772037,"eighty":-3.728167,"marketCap":2600112276},{"date":"2025-12-12","current":-17.896781,"twenty":-7.380142,"median":-4.779357,"eighty":-3.742192,"marketCap":2666065586},{"date":"2025-12-19","current":-17.433215,"twenty":-7.489402,"median":-4.800924,"eighty":-3.751648,"marketCap":2597008591},{"date":"2025-12-26","current":-17.214453,"twenty":-7.525937,"median":-4.815979,"eighty":-3.763383,"marketCap":2564419896},{"date":"2026-01-02","current":-17.063404,"twenty":-7.573901,"median":-4.841253,"eighty":-3.771122,"marketCap":2541918178},{"date":"2026-01-09","current":-15.698748,"twenty":-7.596248,"median":-4.85056,"eighty":-3.792677,"marketCap":2338626798},{"date":"2026-01-16","current":-17.235288,"twenty":-7.641035,"median":-4.868549,"eighty":-3.827277,"marketCap":2567523581},{"date":"2026-01-23","current":-17.756149,"twenty":-7.65516,"median":-4.878917,"eighty":-3.836222,"marketCap":2645115711},{"date":"2026-01-30","current":-17.49051,"twenty":-7.716495,"median":-4.891913,"eighty":-3.850233,"marketCap":2605543725},{"date":"2026-02-06","current":-17.157159,"twenty":-7.797537,"median":-4.900675,"eighty":-3.876725,"marketCap":2555884762},{"date":"2026-02-13","current":-18.146794,"twenty":-7.885881,"median":-4.903471,"eighty":-3.891573,"marketCap":2703309809},{"date":"2026-02-17","current":-19.079135,"twenty":-7.914537,"median":-4.904915,"eighty":-3.895953,"marketCap":2842199721}],"updateTime":1771410855611},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612456064","title":"Spyre Therapeutics presents 20-week Phase 1 SPY003 data at ECCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612456064","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612456064?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419626,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. announced that it will present scientific posters at the 21st Congress of the European Crohn's and Colitis Organisation  on follow-up interim Phase 1 results for SPY003, a half-life extended anti-IL-23 monoclonal antibody being developed for inflammatory bowel disease. The company said the interim data include follow-up out to 20 weeks and will be presented in a poster suggesting potential for quarterly or twice-yearly maintenance dosing. Spyre also said it will present details of SKYLINE-UC, a platform trial in ulcerative colitis evaluating three long-acting antibodies as single agents and in combinations, along with preclinical mouse colitis data on combined anti-TL1A and anti-IL-23 therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL6y0ksx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","SG9999014005.SGD","SYRE","NDAQ","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD","BK4588","IE00BGHQF748.EUR","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2609511800","title":"Spyre Therapeutics vergibt neue Aktienoptionen an Mitarbeiter als Vergütungsanreiz","url":"https://stock-news.laohu8.com/highlight/detail?id=2609511800","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609511800?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:01","pubTimestamp":1770411701,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. hat bekannt gegeben, dass der Vergütungsausschuss des Unternehmens Aktienoptionen zum Erwerb von insgesamt 30.200 Stammaktien an fünf nicht-leitende Mitarbeitende als Eigenkapital-Zusatzvergütung gem dem 2018 Equity Inducement Plan gewhrt hat. Die Optionen haben eine Laufzeit von zehn Jahren, einen Ausübungspreis von 32,75 US-Dollar pro Aktie und unterliegen einem gestaffelten Vesting über vier Jahre, beginnend mit einem Viertel nach einem Jahr und anschlieender monatlicher Freigabe.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 06, 2026, and is solely responsible for the information contained ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL7LfGvf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","SG9999014039.USD","SYRE","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","NDAQ","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2609651156","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2609651156","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609651156?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:01","pubTimestamp":1770411660,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb.  06, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and ant","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/06/3234069/0/en/Spyre-Therapeutics-Announces-Grants-of-Inducement-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SYRE","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2609468243","title":"Spyre Therapeutics CEO Cameron Turtle Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609468243","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609468243?lang=en_us&edition=fundamental","pubTime":"2026-02-05 10:34","pubTimestamp":1770258845,"startTime":"0","endTime":"0","summary":"Cameron Turtle, Chief Executive Officer and Director of Spyre Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL9jMrKy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CEO Cameron Turtle Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2606297632","title":"Spyre Therapeutics Grants Stock Options to New Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606297632","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606297632?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:50","pubTimestamp":1769413841,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. has granted stock options to purchase 108,155 shares of common stock to Kate Chevlen in connection with her appointment as Chief Commercial Officer. The options have a 10-year term and an exercise price of $34.09 per share, reflecting the closing price on January 22, 2026. Vesting terms specify that one-fourth of the options will vest on the first anniversary of Chevlen’s start date, with the remainder vesting monthly over the following three years, contingent on continued service with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 23, 2026, and is solely responsible for the informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDLcfj5mr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","SYRE","BK4139","BK4112","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2606292897","title":"Spyre Therapeutics Appoints Kate Chevlen as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606292897","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606292897?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:23","pubTimestamp":1769412201,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief on January 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL4TN9sx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2605855312","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2605855312","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605855312?lang=en_us&edition=fundamental","pubTime":"2026-01-24 05:00","pubTimestamp":1769202000,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan.  23, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and ant","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/23/3225057/0/en/Spyre-Therapeutics-Announces-Grants-of-Inducement-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","SYRE","BK4539","LENZ"],"gpt_icon":0},{"id":"2604613704","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Spyre Therapeutics (SYRE) and Astellas Pharma (OtherALPMF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604613704","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604613704?lang=en_us&edition=fundamental","pubTime":"2026-01-20 01:30","pubTimestamp":1768843850,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (LLY – Research Report), Spyre Therapeutics (SYRE ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-eli-lilly-co-lly-spyre-therapeutics-syre-and-astellas-pharma-otheralpmf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-eli-lilly-co-lly-spyre-therapeutics-syre-and-astellas-pharma-otheralpmf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJLML261.HKD","LU0323591593.USD","LU2112291526.USD","LU0225283273.USD","LU0689472784.USD","LU0432979614.USD","LU2471134952.CNY","SG9999001176.USD","LU1291159041.SGD","LU0471298694.HKD","IE00BJJMRY28.SGD","LU1232071149.USD","LU1267930730.SGD","LU1974910355.USD","LU2264538146.SGD","LU0256863811.USD","LU0109394709.USD","LU0708995401.HKD","LU2211815571.USD","LU2237443549.SGD","LU2265009873.SGD","LU2360106947.USD","LU2361044949.HKD","LU1366192091.USD","LU0079474960.USD","LU1280957306.USD","LU2491050154.USD","LU2168564222.USD","SG9999015945.SGD","SGXZ99366536.SGD","LU0289739699.SGD","LU0198837287.USD","LU0238689110.USD","LU1064131342.USD","SG9999014898.SGD","IE0004445239.USD","LU2417539215.USD","BK4137","LU0354030511.USD","LU2023250504.SGD","LU0353189680.USD","IE00B4JS1V06.HKD","IE00BFSS7M15.SGD","LU0823416689.USD","LU1551013342.USD","IE00B1BXHZ80.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","SG9999018865.SGD","LU0820561909.HKD","LU1868836757.USD","IE00B7KXQ091.USD","LU2750360641.GBP","IE00B1XK9C88.USD","LU0106261372.USD","LU0889565916.HKD","IE00BJJMRX11.SGD","LU1548497426.USD","LU2491049909.HKD","LU2237443978.SGD","LU2746668974.SGD","LU1720051017.SGD","LU2087625088.SGD","LU0354030438.USD","LU2750360997.AUD","SGXZ81514606.USD","LU1868837136.USD","LU2357305700.SGD","IE00B4R5TH58.HKD","LU0820561818.USD","LU1093756168.USD","LU1023059063.AUD","IE0004445015.USD","LU1127390331.HKD","LU2106854487.HKD","BK4534","LU1093756325.SGD","LABU","LU0128526141.USD","LU0640476718.USD","IE0009355771.USD","LU0061475181.USD","BK4139","IE00BKPKM429.USD","LU0058720904.USD","LU0256863902.USD","IE00BK4W5M84.HKD","LU0943347566.SGD","BK4533","LU2324357040.USD","LU0316494557.USD","LU1623119135.USD","SGXZ57979304.SGD","LU0266013472.USD","IE00BKDWB100.SGD","LU0417517546.SGD","LU1712237335.SGD","LU1868837300.USD","LU2471134879.HKD","BK4599","LLY","LU2491050071.SGD","LU0823434583.USD","SG9999018857.SGD","LU0786609619.USD","LU0096364046.USD","SG9999014906.USD","SGXZ51526630.SGD","SGXZ31699556.SGD","BK4007","LU1917777945.USD","LU2461242641.AUD","LU2063271972.USD","LU2236285917.USD","LU2746668461.USD","LU1868836591.USD","LU2237443895.HKD","LU2089984988.USD","LU2552382058.USD","LU0823434740.USD","SG9999013999.USD","LU0006306889.USD","IE00BJJMRZ35.SGD","SG9999015978.USD","XBI","BK4581","LU1720051108.HKD","LU0097036916.USD","IE00B2B36J28.USD","LU2361045086.USD","LU2552382215.SGD","SYRE","LU0456855351.SGD","LU1988902786.USD","LU0672654240.SGD","LU0109391861.USD","LU2471134796.USD","IE0002141913.USD","LU0203202063.USD","LU2456880835.USD","IE00B775H168.HKD","LU0320765059.SGD","LU2108987350.USD","LU2237443465.HKD","LU2168564495.EUR","LU2237443622.USD","BK4588","LU0385154629.USD","LU1989771016.USD","LU1814569148.SGD","LU2237443382.USD","LU0683600562.USD","LU1983299246.USD","SG9999014880.SGD","IE00BFSS8Q28.SGD","LU2462157665.USD","SG9999015952.SGD","LU0203201768.USD","SG9999001176.SGD","LU2361044865.SGD","LU0320765992.SGD","LU2602419157.SGD","LU0787776722.HKD","LU2168564065.EUR","SG9999014914.USD","BK4516","IE00BN29S564.USD","LU1868836914.USD","LU2168563687.JPY","LU2552382132.HKD","SG9999017495.SGD","LU1057294990.SGD","LU0094547139.USD","GB00BDT5M118.USD","LU0471298777.SGD","LU0029874061.USD","IE0005OL40V9.USD","LU2168564149.EUR","LU1323610961.USD","LU0882574139.USD","ALPMF","LU1061106388.HKD","LU0466842654.USD","LU2471134523.USD","LU1069344957.HKD","IE00BK4W5L77.USD","LU2237438978.USD","BK4585","LU1551013425.SGD","LU1804176565.USD","IE00BWXC8680.SGD","LU2468319806.SGD","LU0234572021.USD","LU0353189763.USD","LU0114720955.EUR","LU0882574055.USD","SG9999015986.USD","IE00BJT1NW94.SGD","LU1035775433.USD"],"gpt_icon":0},{"id":"2603638164","title":"Wedbush Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603638164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603638164?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:38","pubTimestamp":1768315107,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Buy rating on Spyre Therapeutics today and set a price target of $65.00. In addition to Wedbush, Spyre Therapeutics al...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-buy-rating-on-spyre-therapeutics-syre-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-buy-rating-on-spyre-therapeutics-syre-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE"],"gpt_icon":0},{"id":"2602431275","title":"Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2602431275","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602431275?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:51","pubTimestamp":1768225879,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) highlighted its 2026 priorities including six expected POC readouts. The Company also expanded its leadership team with t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-highlights-2026-priorities-appoints-cheveln-as-cco-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-highlights-2026-priorities-appoints-cheveln-as-cco-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","CCO","BK4009","BK4007","LU2506951792.HKD","LU0823414478.USD","LU0823414551.USD","BK4139","LU2294711713.HKD","LU2357125470.USD","LU2249611893.SGD","SYRE"],"gpt_icon":0},{"id":"2602251068","title":"BRIEF-Spyre Therapeutics Inc - Skyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2602251068","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602251068?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:05","pubTimestamp":1768223101,"startTime":"0","endTime":"0","summary":"BRIEF-Spyre Therapeutics Inc - Skyline Trial In UC Completes SPY001 Enrollment Ahead Of ScheduleJan 12 (Reuters) - Spyre Therapeutics Inc SYRE.O:SPYRE THERAPEUTICS INC - SKYLINE TRIAL IN UC COMPLETES ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2602819510","title":"Spyre Therapeutics Appoints Kate Tansey Chevlen as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602819510","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602819510?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:01","pubTimestamp":1768222898,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. has appointed Kate Tansey Chevlen as Chief Commercial Officer. She joins the company from Amgen, where she served as VP, Global Marketing Head for Immunology and Inflammation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3XFJfj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014013.SGD","LU1023059063.AUD","LU0320765992.SGD","BK4566","BK4599","LU1061106388.HKD","BK4112","LU0868494617.USD","IE0009355771.USD","LU0109394709.USD","IE0002141913.USD","LU2242652126.USD","IE00B2B36J28.USD","LU0314104364.USD","SG9999001440.SGD","LU2112291526.USD","LU0058720904.USD","SG9999014005.SGD","SG9999014039.USD","NDAQ","LU0889565916.HKD","LU2242646821.SGD","IE00BJT1NW94.SGD","IE00BKPKM429.USD","LU2089984988.USD","BK4581","AMGN","SYRE","IE00BFTCPJ56.SGD","IE00B64PRP62.GBP","LU1571399168.USD","LU1983299246.USD","BK4534","LU0289739699.SGD","LU1057294990.SGD","LU2095319765.USD","LU2210149790.SGD","IE00B4R5TH58.HKD","LU0122379950.USD","IE00B3QW5Z07.USD","BK4533","BK4588","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","LU2468319806.SGD","SG9999014021.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2602510806","title":"Spyre Therapeutics Inc - Skyline Trial in Uc Completes Spy001 Enrollment Ahead of Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510806?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:01","pubTimestamp":1768222874,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2602510381","title":"Spyre Therapeutics Inc: Skyline Part a Readouts Accelerated, NOW Expected to Start in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510381","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510381?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:01","pubTimestamp":1768222874,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2602361510","title":"Spyre Therapeutics Inc - Skyway Trial Readouts Expected in 4Q 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602361510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602361510?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:01","pubTimestamp":1768222874,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0SQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2602510876","title":"Press Release: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510876","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510876?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"\"6 in '26\" expected proof-of-concept  readouts across SKYLINE and SKYWAY trials. SKYLINE platform trial in ulcerative colitis  recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2. SKYWAY basket trial enrollment on track across rheumatoid arthritis , psoriatic arthritis , and axial spondyloarthritis ; All readouts expected in 4Q 2026. WALTHAM, Mass., Jan. 12, 2026  -- Spyre Therapeutics, Inc. , a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease  and rheumatic diseases, today highlighted its 2026 priorities including six expected POC readouts . The Company also expanded its leadership team with the appointment of Kate Tansey Chevlen as CCO. Ms. Tansey Chevlen is a seasoned biopharma commercial leader with nearly two decades of experience driving strategy, execution, and growth across U.S. an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2249611893.SGD","BK4139","LU0823414551.USD","BK4539","BK4009","LU0823414478.USD","LU2357125470.USD","CCO","LU2294711713.HKD","LU2506951792.HKD","RA","LENZ","SYRE","BK4007"],"gpt_icon":0},{"id":"2602662318","title":"Spyre Therapeutics Grants Stock Options to Six New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2602662318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602662318?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:06","pubTimestamp":1767906418,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. has granted stock options to six non-executive employees as equity inducement awards under its 2018 Equity Inducement Plan. The awards cover a total of 42,000 shares of common stock with an exercise price of $30.58 per share, reflecting the closing price on January 2, 2026. Each option has a ten-year term and vests over four years, with one-fourth of the shares vesting on the first anniversary of the employee's start date and the remainder vesting in equal monthly installments thereafter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL4QV6f1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4112","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","LU0314104364.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","NDAQ","SG9999014013.SGD","LU2095319765.USD","BK4588","SYRE"],"gpt_icon":0},{"id":"2602313990","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2602313990","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602313990?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:05","pubTimestamp":1767906300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan.  08, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and ant","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215780/0/en/Spyre-Therapeutics-Announces-Grants-of-Inducement-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","SYRE","BK4139","BK4007"],"gpt_icon":0},{"id":"2601828317","title":"Spyre Therapeutics CEO Cameron Turtle Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828317","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601828317?lang=en_us&edition=fundamental","pubTime":"2026-01-07 10:37","pubTimestamp":1767753430,"startTime":"0","endTime":"0","summary":"Cameron Turtle, Chief Executive Officer and Director of Spyre Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL2wl25h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CEO Cameron Turtle Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2601600588","title":"Spyre Therapeutics (SYRE) Valuation Check After Recent Drop And Focus On 2026 Trial Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2601600588","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601600588?lang=en_us&edition=fundamental","pubTime":"2026-01-06 13:21","pubTimestamp":1767676873,"startTime":"0","endTime":"0","summary":"Event driven move in Spyre Therapeutics\nSpyre Therapeutics (SYRE) shares fell about 7% on 2 January 2026, as traders reacted to biotech sector volatility and refocused on the company’s key 2026 clinical readouts for SKYLINE-UC and SKYWAY-RD.\nSee our latest analysis for Spyre Therapeutics.\nThat 7% single day fall sits within a choppy but strong backdrop, with a 90 day share price return of 69.46% and a 1 year total shareholder return of 23.04%. This suggests momentum has cooled recently after...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-check-after-recent-drop-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-check-after-recent-drop-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SYRE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":64,"code":"91000000","status":"200"}]}}